Despite showing no meaningful benefit on lung function, Arcturus’ mRNA therapy ARCT-032 reduced mucus volume in patients with ...

An international team led by Monash University researchers has uncovered the genetic code governing the way genetic mutations affect mRNA and result in disease.

Arcturus Therapeutics Holdings Inc. faces a solid cash runway into 2028, pipeline setbacks, and risk/reward profile. Learn ...

Therapeutics and Global Markets" report has been added to ResearchAndMarkets.com's offering.The global market for mRNA therapeutics was valued at $7.71 billion in 2025 and is forecast to remain stable ...

Arcturus Therapeutics shares plunged 56% after Phase 2 cystic fibrosis trial data showed no meaningful lung function ...

A new preliminary study published in Nature suggests that COVID-19 vaccines might actually boost the immune system to make ...

Tardigrades make a unique damage suppressor protein that researchers are working to harness for medicine, space, agriculture, ...

Arcturus Therapeutics (ARCT) stock falls as Citi downgrades the company following weak mid-stage trial data for its cystic ...

Groundbreaking research reveals mRNA COVID-19 vaccines may significantly boost cancer treatment. A study found patients ...

Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients ...

This important study examines the potential role of ARHGAP36 transcriptional regulation by FOXC1 in controlling sonic hedgehog signaling in human neuroblastoma. While there are many solid findings ...